Publications 2024

Abdul Halim A, Abreu P, Aglietta M, Allekotte I, Cheminant KA, Almela A, Aloisio R, Alvarez-Muñiz J, Yebra JA, Anastasi GA, Anchordoqui L, Andrada B, Andringa S, Anukriti, Apollonio L, Aramo C, Ferreira PRA, Arnone E, Velázquez JCA, Assis P, Avila G, Avocone E, Bakalova A, Barbato F, Mocellin AB et al. (2024)
Demonstrating Agreement between Radio and Fluorescence Measurements of the Depth of Maximum of Extensive Air Showers at the Pierre Auger Observatory
Phys Rev Lett, 132 (2), 021001
DOI 10.1103/PhysRevLett.132.021001, PubMed 38277596

Publications 2023

Fortner RT, Trewin-Nybråten CB, Paulsen T, Langseth H (2023)
Characterization of ovarian cancer survival by histotype and stage: A nationwide study in Norway
Int J Cancer, 153 (5), 969-978
DOI 10.1002/ijc.34576, PubMed 37226635

Publications 2022

Paulsen T, Liland H, Myklebust TÅ, Lindemann K (2022)
Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study
Int J Gynecol Cancer, 32 (2), 181-188
DOI 10.1136/ijgc-2021-002898, PubMed 34987096

Publications 2018

Noer MC, Leandersson P, Paulsen T, Rosthøj S, Antonsen SL, Borgfeldt C, Høgdall C (2018)
Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - a comparative cohort study
Acta Oncol, 57 (8), 1100-1108
DOI 10.1080/0284186X.2018.1440085, PubMed 29451070

Szczesny W, Langseth H, Myklebust TÅ, Kaern J, Tropé C, Paulsen T (2018)
Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study
Acta Obstet Gynecol Scand, 97 (8), 956-965
DOI 10.1111/aogs.13361, PubMed 29790149

Publications 2016

Szczesny W, Vistad I, Kaern J, Nakling J, Tropé C, Paulsen T (2016)
Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival
Eur J Gynaecol Oncol, 37 (3), 305-11
DOI 10.12892/ejgo3007.2016, PubMed 27352555

Publications 2014

Solheim O, Tropé CG, Rokkones E, Kærn J, Paulsen T, Salvesen HB, Hagen B, Vereide AB, Fosså SD (2014)
Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
Gynecol Oncol, 136 (2), 224-9
DOI 10.1016/j.ygyno.2014.12.010, PubMed 25511159

Publications 2011

Paulsen T, Kærn J, Tropé C (2011)
Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery
Gynecol Oncol, 122 (1), 83-8
DOI 10.1016/j.ygyno.2011.02.038, PubMed 21435701

Publications 2009

Tropé C, Davidson B, Paulsen T, Abeler VM, Kaern J (2009)
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
Eur J Gynaecol Oncol, 30 (5), 471-82
PubMed 19899396

Publications 2008

Maehle L, Apold J, Paulsen T, Hagen B, Løvslett K, Fiane B, Van Ghelue M, Clark N, Møller P (2008)
High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers
Clin Cancer Res, 14 (22), 7569-73
DOI 10.1158/1078-0432.CCR-08-0112, PubMed 19010876

Publications 2007

Paulsen T (2007)
Epithelial ovarian cancer: a clinical epidemiological approach on diagnosis and treatment
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 549, 1 b. (flere pag.)
BIBSYS 08003618x, ISBN 978-82-8072-439-7

Paulsen T, Ree AH, Kaern J, Kjaerheim K, Bassarova A, Berner A, Haldorsen T, Tropé C, Nesland JM (2007)
Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
Eur J Gynaecol Oncol, 28 (5), 356-63
PubMed 17966213

Publications 2006

Paulsen T, Kaern J, Kjaerheim K, Haldorsen T, Tropé C (2006)
Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer
Gynecol Oncol, 102 (3), 447-52
DOI 10.1016/j.ygyno.2006.01.035, PubMed 16516277

Paulsen T, Kjaerheim K, Kaern J, Tretli S, Tropé C (2006)
Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals
Int J Gynecol Cancer, 16 Suppl 1, 11-7
DOI 10.1111/j.1525-1438.2006.00319.x, PubMed 16515561

Publications 2005

Paulsen T, Kaern J, Kjaerheim K, Tropé C, Tretli S (2005)
Symptoms and referral of women with epithelial ovarian tumors
Int J Gynaecol Obstet, 88 (1), 31-7
DOI 10.1016/j.ijgo.2004.09.008, PubMed 15617702

Publications 2001

Paulsen T, Kjaerheim K, Kaern J, Norstein J, Onsrud M (2001)
[Examination, treatment and follow-up of ovarian cancer in Norway]
Tidsskr Nor Laegeforen, 121 (23), 2696-700
PubMed 11699376

Publications 2000

Paulsen T, Marth C, Kaern J, Nustad K, Kristensen GB, Tropé C (2000)
Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients
Gynecol Oncol, 76 (3), 326-30
DOI 10.1006/gyno.1999.5699, PubMed 10684705

Tropé C, Paulsen T, Baekelandt M, Makar A (2000)
[Controversies in surgical treatment of advanced ovarian cancer]
Tidsskr Nor Laegeforen, 120 (7), 824-30
PubMed 10806907

Publications 1998

Paulsen T, Kaern J, Tropé C (1998)
Carboplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up
Eur J Gynaecol Oncol, 19 (6), 524-8
PubMed 10215433